| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a412a5d1b2dbe3cee616dbc52e1489 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da3910a67b3c97a1fe2c7c93d10a6cef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49db7314e24000f03f876ccaff489f2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ddf54865e77fff4e38b301ddb5fa936
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bffdb5f4f48ac49607ebd728954468e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e03b3504b1cc6dfb403963ddf811691 |
| publicationDate |
2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020087414-A1 |
| titleOfInvention |
STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN |
| abstract |
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018362668-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022140797-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11168149-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10947319-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023086772-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11286293-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023004425-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021214460-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11325981-B2 |
| priorityDate |
2011-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |